Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Voyageur Pharmaceuticals Secures USD $1.9 Million Sales Contract for SmoothX 2% (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
CytoDyn Inc
CYDY
Healthcare
Biotechnology
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The Company is studying leronlimab in multiple therapeutic areas, including...
infectious disease, cancer, and autoimmune conditions. Its core areas of clinical development are human immunodeficiency viruses (HIV), non-alcoholic steatohepatitis (NASH), and solid tumors in oncology. The areas of clinical focus in HIV are the lifting of the clinical hold, creation of a long-acting formulation of leronlimab and an HIV functional cure in using adenovirus vectors (AAV). In NASH, its focus is on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Regarding oncology, its focus remains on combination therapy for solid tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
OTCQB:CYDY - Post Discussion
CytoDyn Inc
> Clear as mud, just kidding.
New Post
View:
Discussion
List
(2)
•••
theNorm
X
View Profile
View Bullboard History
Post by
theNorm
on Jul 01, 2020 10:09pm
Clear as mud, just kidding.
Possible class action lawsuit to develop by shareholders against this short and distort author. A classic opportunity for people to buy on the dips.
Clarifications and amazing news moving forward!
www.youtube.com/watch?time_continue=3&v=TwdjWhWV1nc&feature=emb_logo
CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan addressed the recent report published by short seller Citron Research, entitled "SEC must immediately halt this...
CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan addressed the recent report published by short seller Citron Research, entitled "SEC must immediately halt this...
www.youtube.com
Reply
Replies (2)
9
(2)
•••
tikotiko
X
View Profile
View Bullboard History
Comment by
tikotiko
on Jul 01, 2020 11:40pm
Yes, it will be bumpy...
(2)
•••
theNorm
X
View Profile
View Bullboard History
Comment by
theNorm
on Jul 02, 2020 5:20pm
Trading like they are still shorting it. Just wait a week or two and CYDY will burn them with promo and more good patient results. Think they are already burned just trying to double down and getting burned even harder by the way the sp still bounces back after every short. I don't even have this on my watchlist anymore, since I am riding for free.
...more
(2)
•••
tikotiko
X
View Profile
View Bullboard History
Comment by
tikotiko
on Jul 02, 2020 8:32pm
I agree and also plan to ride this very long by taking profits here and there. The next few weeks will be very exciting!
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
This Gambling Tech Stock Might be the Safest Bet you’ll make this Year
April Sees Record Revenue for Cannabis Edibles Leader and Eyes Record Profitability in 2024